echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Express to further test the Aduhelm effect, Bojian plans to start confirmatory clinical trials

    Express to further test the Aduhelm effect, Bojian plans to start confirmatory clinical trials

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    ▎Editor of WuXi AppTec content team On December 16, 2021, Biogen and Eisai announced that they are expected to start a large confirmatory clinical trial in May next year to further evaluate Alzheimer’s The efficacy of monoclonal antibody therapy Aduhelm (aducanumab) for disease (AD)

    Aduhelm received accelerated approval from the US FDA in June of this year.
    It is the first time the FDA has approved a new treatment for AD since 2003

    Biogen plans to submit the final clinical trial plan to the FDA in March 2022.
    If approved by the FDA, patient screening will be initiated in May 2022.
    The main clinical endpoint will be evaluated 18 months after the start of treatment

     Aducanumab is a monoclonal antibody that directly targets amyloid beta (Aβ)

    The accumulation of Aβ in the brain is a clear pathophysiological feature of AD

    Aducanumab is suitable for the treatment of patients with mild cognitive impairment due to AD or in the early stage of dementia (dementia).
    These patients have confirmed the presence of Aβ deposits in the brain through PET scans

    Aduhelm's approval in June was based on the accelerated approval channel

    This channel is used to approve innovative therapies for the treatment of serious or life-threatening diseases

    A statement issued by the FDA pointed out that Aduhelm’s accelerated approval is based on its impact on the surrogate endpoint, which consistently reduces the levels of amyloid plaque in the brains of patients in phase 3 clinical trials

    However, the FDA also requires Bojian to conduct confirmatory clinical trials after obtaining accelerated approval to prove the clinical benefit of Aduhelm on the cognitive abilities of AD patients

    Image source: 123RF Bojian press release stated that this trial will recruit more than 1,300 early-stage AD patients.
    Other details of the trial design, including the trial endpoints, have not been disclosed

    Based on previous experience, Bojian predicts that this test will take about 4 years to complete, which means that data may not be available until 2026 at the earliest

    In addition, Bojian is waiting for the Phase 3 clinical trial data of another AD treatment drug, lecanemab, which is expected to be available in the middle of 2022

    Reference materials: [1] Biogen Preps for Post-Approval Testing of Controversial Alzheimer's Drug.
    Retrieved December 16, 2021, from https:// -s-drug-aduhelm/[2] All Approvals and Tentative Approvals December 2021.
    Retrieved December 16, 2021, from https:// .
    process[3] As Aduhelm faces doubts, Biogen plans another pivotal trial for 2022.
    Retrieved December 16, 2021, from https:// -plans-another-pivotal-trial-for-2022/Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress

    This article is for the purpose of information exchange only.
    The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article

    This article is not a treatment recommendation either

    If you need guidance on the treatment plan, please go to a regular hospital for treatment

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.